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Electrical stimulation (ES) is a therapeutic treatment for wound healing. Electroporation, a type of ES, is a well-
established method for gene delivery. We hypothesize that proper conditions can be found with which both elec-
trical and gene therapies can be additively applied to treat diabetic wound healing. For the studies of transforming
growth factor-b1 (TGF-b1) local expression and therapeutic effects, full thickness excisional wound model of db/db
mice was used, we measured TGF-b1 cytokine level at 24 h postwounding and examined wounds histologically.
Furthermore, wound closure was evaluated by wound-area measurements at each day for 14 d. We found that
syringe electrodes are more effective than the conventional caliper electrodes. Furthermore, diabetic skin was
more sensitive to the electroporative damage than the normal skin. The optimal condition for diabetic skin was six
pulses of 100 V per cm for 20 ms. Under such condition, the healing rate of electrically treated wound was
significantly accelerated. Furthermore, when TGF-b1 gene was delivered by electric pulses, the healing rate was
further enhanced. Five to seven days postapplication of intradermal injection of plasmid TGF-b1 followed by
electroporation, the wound bed showed an increased reepithelialization rate, collagen synthesis, and angiogen-
esis. The data indicates that indeed the electric effect and gene effect work synergistic in the genetically diabetic
model.
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Wound healing is compromised in diabetic mellitus. The
patients have difficulty regeneration the skin barrier, result-
ing in ulceration and even infection. The impairment has
previously been identified as impaired cellular infiltration,
collagen, and granulation tissue formation (Brown et al,
1997). Several studies have reported that growth factor or
its receptor deficiencies relate to diabetes-induced impair-
ment of wound healing. Beer et al (1997) demonstrated a
reduced expression of PDGF A and B and of A-type recep-
tor in wounded or unwounded diabetic skin. An IGF-1 re-
duction of 42% in wound fluid and of 48% in serum was
observed in diabetes-related impairment (Bitar and Labbad,
1996). A 55% reduction of transforming growth factor-b1
(TGF-b1) expression in diabetic wound fluid has also been
shown in the same study.
The administration of exogenous growth factors have
been successfully used to accelerate the pathologic wound
healing in human and animal models. Topical administration
of PDGF-BB-stimulated wound healing in genetically dia-
betic mice (Greenhalgh et al, 1990) and was eventually ap-
proved by the FDA for treating diabetic ulcer. A single dose
of TGF-b in a collagen vehicle can restore the diabetes-
related decrease in tensile strength of collagen (Bitar and
Labbad, 1996). Broadley et al (1989–1990) also reported
that injection of TGF-b-induced accumulation of granulation
tissue, and collagen production and maturation. One dis-
advantage of growth factors, however, are their high ex-
pense. Instead of using growth factors, the recent approach
is to administer a gene that encodes a growth factor (Yao
and Eriksson, 2000). The contribution of growth factor gene
to problematic wound healing in animal models appears
as successful as the growth factor itself, although no direct
comparison has been reported. Subcutaneous injection of
interleukin-6 plasmid to mice restores abnormal wound
healing (Gallucci et al, 2001). In a dermal ulcer model, top-
ical application of PDGF embedded in collagen sponges
promotes reepithelialization, wound closure, and new gran-
ulation tissue formation (Tyrone et al, 2000). In our previous
study, intradermal injection of TGF-b1 gene could acceler-
ate wound closure (Chesnoy et al, 2003). TGF-b1 is a mul-
tifunctional growth factor. It is a chemokine for fibroblasts. It
enhances wound contraction rate, extracellular matrix pro-
duction in vivo (Mustoe et al, 1991; Lanning et al, 2000)
and the formation of capillary in vitro (Sakuda et al, 1992). It
influences tissue repair by activation of Smad signaling
(Dijke et al, 2002). It signals through heteromeric complexes
of type II and type I transmembrane Ser/Thr kinase re-
ceptors, then initiates phosphorylation cascades involving
Abbreviations: BrdU, 5-bromo-2-deoxyuridine; ES, electrical
stimulation; TGF-b1, transforming growth factor-b1
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receptor-regulated Smads, a co-Smad, and inhibitory
Smads.
For decades, investigators have attempted to treat prob-
lems related to wound impairment by electrical stimulation
(ES). Most of the ES applications are safe and effective. For
example, it has long been used in clinics for wound-related
pain control (Evans et al, 2001; Bjordal et al, 2003) and
neuromuscular rehabilitation with an excellent safety record
(Crevenna et al, 2003). Furthermore, electric pulses can
accelerate the recovery of diabetic ulcer (Baker et al, 1997).
In other human studies, ES has been shown to accelerate
the recovery of chronic wounds (Gardner et al, 1999).
Electroporation is a type of electrical treatment that can
enhance cell permeability to allow penetration of macro-
molecules such as DNA (Banga and Prausnitz, 1998). It has
been reported to increase gene transfer in liver and muscle
(Aihara and Miyazaki, 1998; Suzuki et al, 1998). Delivery of
chemotherapeutic agents to cancers using electroporation
has progressed to Phase II clinical trial (Heller et al, 1997;
Heller et al, 1999). Due to the complexity of the skin, harsh
condition of electroporation, which ranged from electric
field strength of 400–2000 V per cm, were mostly used
to accomplish effective gene transfer (Titomirov et al, 1991;
Heller et al, 2001). Typical transdermal voltage for drug de-
livery is 50–150 V (Vanbever et al, 1996). High current and
voltage applied to the skin can cause tissue damage and
electrolysis (Pliquett, 1999). We hypothesized that proper
conditions could be found with which both electrical and
gene therapies could be additively applied to treat diabetic
wound healing without damaging the tissue. The first step of
our study was the optimization of parameters such as ap-
plied voltage, pulse duration, number of pulses, and types
of electrode. We then examined if the optimal condition for
TGF-b1 gene transfer at the wound site could also benefit
healing due to its electric effect.
Results
Optimization of electroporative condition In vivo elect-
roporative gene delivery is commonly accomplished by two
kinds of electrodes: calipers and syringe electrodes, a spe-
cial type of needle electrodes. The design of the syringe
electrode has been previously described (Liu and Huang,
2002). To compare caliper and syringe electrodes in the
effectiveness on gene delivery, we intradermally injected
40 mg of luciferase reporter gene to C57BL/6 or
C57BKS.cgmLeprdb mice followed by electroporation us-
ing caliper or syringe electrodes. We found that the syringe
electrodes were more effective in gene transfer compared
with the caliper electrode. In Fig 1A, the luciferase gene
expression in the syringe-electroporated skin was 10-fold
higher compared with the caliper electroporated skin when
the same applied voltage and duration (100 V in 20 ms) were
used. Therefore, in our further experiment, we decided to
use the syringe electrodes.
To optimize the electroporative condition for the syringe
electrodes, we tested different applied voltage and found
that 100 V for a duration of 20 ms with six pulses was
the optimal condition for gene transfer in the skin tissue
(Fig 1B). Higher voltage did not induce a corresponding in-
crease in the gene expression. Furthermore, when we com-
pared the luciferase gene expression of two skin types
(diabetic and normal), the diabetic skin performed 10-fold
higher expression compared with the normal skin at these
conditions. Bubbles, a sign of electrolysis, were observed
surrounding the electrodes in the diabetic skin when 200 V
per cm field strength was applied. This observation did not
appear in the normal skin, suggesting that the diabetic skin
is more sensitive to electroporation in mouse model.
Local expression of TGF-b1 at the wound bed Next, we
transfected the diabetic skin tissue with our therapeutic
gene, TGF-b1, using the optimized condition. To measure
the skin transfection by the plasmid, we used an ELISA kit,
which was coated with the TGF-b1 receptor to detect hu-
man TGF-b1. As shown in Fig 2, intradermal injection of
plasmid TGF-b1 gave a significantly (po0.05) higher ex-
pression of TGF-b1 compared with the untreated, electrop-
oration alone or intradermal injection of the empty plasmid.
Intradermal injection of plasmid TGF-b1 followed by elect-
roporation produced 2-fold higher cytokine level compared
with the intradermal injection of plasmid TGF-b1 alone,
suggesting that electroporation enhanced the gene transfer
as previously reported (Heller et al, 2000). On the other
hand, the untreated tissue produced low level of TGF-b1
cytokine. Furthermore, wound treated with intradermal in-
jection of empty plasmid or electroporation alone also pro-
duced TGF-b1 cytokine as low as the untreated. These low
levels of activity might arise from the cross-reactivity of the
antibody with endogenous murine TGF-b1.
Figure1
Luciferase activity after electroporation using different electrodes
and electric parameters on normal (A) and diabetic (B) skin.
po0.001, comparing data of 100 V using syringe electrode with all
other conditions; n¼ 6.
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Wound-healing parameters Wound healing is a multiple-
step process. In order to investigate the progress of wound
healing, wound-healing phases such as reepithelialization,
wound closure, collagen synthesis, and angiogenesis were
examined in the diabetic skin.
Reepithelialization Reepithelialization is a process involv-
ing keratinocyte migration followed by keratinocyte prolif-
eration. At day 5 postwounding, hematoxylin & eosin (H&E)
staining showed that the leading end of the epithelium (i.e.
the epithelial tongue schematically shown in Fig 4A) of all
wounds migrated towards the center (from left to right in
Fig 3). The epithelial tongue (indicated by arrow in Fig 3) moved
the fastest in the wound treated with plasmid TGF-b1 in-
jection followed by electroporation. The electric treatment
appears to induce the fibroblast migration. As can be seen
in Fig 3, cell density in the granulation tissue (schematically
shown in Fig 4A) in the wound treated with electroporation
alone (Fig 3B) was higher than in the untreated wound
(Fig 3A). The majority of the observed cells in the granulation
tissue were spindle-like, similar to the shape of fibroblasts.
Anti-5-bromo-2-deoxyuridine (BrdU) immunohistochemical
staining further showed that the epithelial cells were the
most actively proliferated in the electro-TGF-b1 gene-treat-
ed wounds. Cell proliferation was also significantly induced
by simple plasmid TGF-b1 injection. On the contrary, other
treatments produced comparable level of cell proliferation
as the untreated.
When we investigated the epidermal cell proliferation
at the edge of the wound, the proliferation rate (Fig 4B) at
region 2 (Fig 4A) was higher than at region 1, which is the
leading edge of the epithelial tongue. The difference tends
to be significant (po0.05) in the actively proliferated wound
bed that received the plasmid TGF-b1. In both locations, the
wound treated with intradermal injection of the TGF-b1
gene followed by electroporation induced higher prolifera-
tion than other treatments. Intradermal injection of plasmid
TGF-b1 also induced proliferation significantly (po0.05) in
both positions compared with the untreated, electropora-
tion, intradermal injection of the empty plasmid with or
without electroporation.
Wound closure Wound contraction is the process to min-
imize the open area by pulling the neighboring tissue to-
wards the wound center. Myofibroblasts differentiated from
fibroblasts generate the contractile force (Jester et al, 1999;
Feugate et al, 2002). It occurs faster than reepithelialization
Figure 2
Transforming growth factor-b1 (TGF-b1) cytokine level 24 h after
the following treatments: electroporation only (E), intradermal in-
jection of empty plasmid [ID(TGF)] or plasmid with TGF-b1 gene
[ID(empty)], electroporation following intradermal injection of plas-
mid with [ID(TGF)þE] or without TGF-b1 gene [ID(empty)þE].
po0.001, comparing treatment of TGF-b1 gene by electric pulses
with all other treatments. po0.05, comparing treatment of TGF-b1
gene by intradermal injection with all other treatments; n¼6.
Figure 3
Hematoxylin & eosin staining for
wound morphology at day 5 after the
following treatments. Wound treated
without (A, C, and E) or with electropora-
tion (B, D, and F). No injection of plasmid
(A, B), injection of empty plasmid (C, D) or
plasmid with TGF-b1 gene (E, F). Epithe-
lial tongue is indicated by black arrow.
Epidermal tissue, granulation tissue, and
smooth muscle is indicated, respectively,
as E, G, and SM. Magnification  100.
WOUND HEALING BY ELECTRIC DELIVERY OF TGF-b1 GENE 793123 : 4 OCTOBER 2004
because no cell proliferation is involved. We evaluated
the wound-contraction rate by measuring the percentage
of wound closure until wound is completely closed at day
14 (Fig 5). When compared with the untreated group
throughout the 14 d, all treatments such as electropora-
tion alone, and intradermal injection of plasmid TGF-b1 with
or without electroporation induced greater wound contrac-
tion. Wound-closure rate was significantly (po0.05) accel-
erated at early stages (days 2–5) in the electro-TGF-b1
gene-treated wound bed compared with TGF-b1 gene-
treated wound bed. This suggests that additive effect of
electroporation combined with TGF-b1 gene treatment on
wound closure occurred only in the early phase of wound
healing.
Collagen synthesis At day 5 after treating with intradermal
injection of plasmid TGF-b1 with or without electroporation,
high intensity of collagen was found in the newly formed
granulation tissue at the epithelial tongue, with the former
being higher than the latter (Fig 6). The collagen organiza-
tion in the electric-gene-treated wound appeared the most
mature, as it resembled the unwounded skin at day 5 (Fig
6F,G). In addition, we observed that the collagen organi-
zation in the smooth muscle layer (white arrow, Fig 6D) is
more dispersed from the granulation tissue.
Figure 4
Immunostaining for 5-bromo-2-deoxyuridine
(BrdU)-positive keratinocytes at the wound edge
of the epithelium at day 3 postwounding follow-
ing different treatments. (A) Schematic drawing of
a wound indicating the location of cell counts taken
(regions 1 and 2). (B) BrdU-positive cell count at
region 1 (&) or at region 2 (’) following different
treatments; n¼ 3.
Figure5
Wound contraction as percentage of wound closure during 14 d
after electroporation alone (PBSe), or plasmid transforming growth
factor-b1 (TGF-b1) injection with (TGFe) or without electroporation
(TGF). Control represents untreated wound. po0.05, comparing the
treatment of TGF-b1 gene followed by electric pulses with treatment of
TGF-b1 gene; n¼ 12.
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Angiogenesis Angiogenesis is a process for new capillary
growth and one of its components is endothelial cell migra-
tion (Lingen and Nickoloff, 2001). At day 7, sections of har-
vested wound bed were stained with anti-factor VIII-related
antigen to identify endothelial cells in the newly synthesized
granulation tissue in the wound. A higher density of end-
othelial cells was found in the electro-TGF-b1 gene-treated
wound than was found in all other treatments. In the wound
bed treated with simple injection of TGF-b1 gene, stained
endothelial cells could be observed in one of the three rep-
resentative fields (black arrow, Fig 7E). On the other hand,
with electroporation, more intensely stained endothelial cells
were observed in all three fields (Fig 7F). The number of
stained endothelial cells found in different treatment groups
is shown in Fig 7G. Only electro-TGF-b1 gene therapy ap-
peared to enhance endothelial cell migration significantly
(po0.05), suggesting an enhanced angiogenesis.
Discussion
This report demonstrates the potential of the combination of
gene and electric therapies to treat diabetic wound healing.
For this purpose, we looked for conditions in which both
TGF-b1 gene transfer and electrical treatment occurred. We
started the experiment searching for the optimal condition
for enhancing gene transfer. We applied electric pulses
immediately after injection of the luciferase reporter gene.
We found that six pulses of 100 V per cm in 20 ms duration
with the syringe electrodes was the most effective condi-
tion, and accomplished transfection level of approximately
107 RLU per mg of protein. To achieve a comparable
transfection level, most of the investigators used the electric
field 700–1200 V per cm (Heller et al, 2001) which are 7-fold
higher than our applied electric field. In other words, we
used much milder conditions to produce comparable gene
transfection. This is important since the diabetic skin is
Figure 6
Collagen formation shown by picros-
irius staining at day 5 postwounding
following the treatment of electropora-
tion (B, D, and F) or without electrop-
oration (A, C, and E). No injection of
plasmid (A, B), injection of empty plasmid
(C, D), or plasmid with transforming
growth factor-b1 gene (E, F). (G) Un-
wounded skin. Collagen is indicated as
glowing yellowish orange. Epidermal tis-
sue, granulation tissue, adipose tissue
and smooth muscle is marked as E, G,
A and SM, respectively. Magnification
 200.
Figure7
Angiogenesis at the granulation tissue at the center of the wound
bed (region 3) at day 7 postwounding following the treatment
without (A, C, and E) or with electroporation. (B, D, and F). No in-
jection of plasmid (A, B), injection of empty plasmid (C, D) or plasmid
with transforming growth factor-b1 (TGF-b1) gene (E, F). Endothelial
cells are indicated by black arrow. Magnification  400. (G) Endothelial
cell count in three representative fields. po0.05, comparing the treat-
ment of TGF-b1 gene by electric pulses with all other treatments.
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more sensitive to electoporation than the normal skin in this
mouse model. The use of a mild condition was necessary to
prevent tissue damage.
Then we studied if our optimal condition could bring
about the therapeutic effects of TGF-b1 gene transfer and
electrical therapy. We investigated several well-recognized
wound-healing parameters such as reepithalization, wound
closure, collagen deposition, and angiogenesis with our di-
abetic excisional wound model. We used the same syringe
for the injection of the TGF-b1 gene and the application of
six pulses of 100 V per cm in 20 ms duration without with-
drawing the needle. In this experimental setting, we found
that electric pulses alone could induce cell migration (Fig 3)
and wound closure (Fig 5). Simple injection of TGF-b1
plasmid could induce reepithalization, wound closure, col-
lagen deposition, and angiogenesis. As we expected, the
application of electric pulses along with the delivery of TGF-
b1 plasmid further enhanced all wound-healing parameters.
An increase of reepithelialization rate, wound contraction,
collagen synthesis, and angiogenesis was found in the
wound 5–7 d postapplication of intradermal injection of
TGF-b1 followed by electroporation. Not surprisingly, the
improvements in reepithelialization rate, collagen synthesis,
and angiogenesis were greater than the additive effects of
gene and electric treatments. There was a clear synergism
between the two treatments.
TGF-b1 is a multifunctional cytokine and the biological
response is complicated in wound healing. It is a potent
chemokine for fibroblasts. It enhances granulation tissue
and collagen formation. On the other hand, TGF-b1 is a
potent inhibitor of keratinocyte proliferation in vitro (Garlick
and Taichman, 1994a; Garlick et al, 1996). One possible
reason is that the TGF-b1 pathway is a negative feedback
mechanism for epidermal growth factor-induced prolifera-
tion of human keratinocyte (Yamasaki et al, 2003). In a ster-
oid-impaired rabbit wound model, however, application of
TGF-b1 enhances reepithelialization (Beck et al, 1991). An-
other study further supported that TGF-b1 acted as an in-
ducer in keratinocyte proliferation in vivo. This group
showed that overexpression of TGF-b1 promoted epider-
mal cell growth in a TGF-b1 transgenic model (Fowlis
et al, 1996). Besides keratinocyte proliferation, TGF-b1 can
induce keratinocyte migration by upregulating the synthesis
of laminin 5, which has a dual function in keratinocyte ad-
hesion or migration (Decline et al, 2003). Taken together,
TGF-b1 is beneficial to wound healing. Indeed, the thera-
peutic effect of plasmid TGF-b1 has been fully documented
by our group (Chesnoy et al, 2003). Our data is consistent
with the previous findings.
ES has been known as a cell migration promoter. Studies
showed that electrical field stimulates macrophage, corneal
epithelial cells, and fibroblast migration (Brown and Loew,
1994; Cho et al, 2000; Wang et al, 2003). Our results also
showed that electroporation induces cell migration (Fig 3B).
The induction is associated with an alteration of cell move-
ment including cell crawling and possibly cell rolling without
changing the cell morphology (Cho et al, 2000). The mech-
anism of electric field-induced migration is not yet clearly
elucidated, but integrin-dependent signaling may be in-
volved in electric field-induced macrophage migration (Cho
et al, 2000). Furthermore, the electric stimulation also en-
hances the activation of ERK1/2, a signaling molecule in the
MAP kinase pathway (Wang et al, 2003).
In our study, we found that the actively migrating kera-
tinocytes at the leading end (region 1, Fig 4A) does not
proliferate. Instead, most of the proliferation took place in
the vicinity of the leading end (region 2, Fig 4A). Previous
studies reported that reepithelialization is temporally and
spatially coordinated: keratinocyte migrate into the wound
followed by transiently burst proliferation at the wound
margin, and the actively migrating keratinocytes does not
proliferate (Garlick and Taichman, 1994b). Thus, our data is
consistent with previous findings.
In conclusion, we have proposed an innovative strategy
for therapeutic treatment of diabetes-induced wound impair-
ment with a combination of electric and gene therapies that
may have a significant implication for clinical applications.
Materials and Methods
Animal Female mice of C57BL/6 or C57BKS.Cg-mþ /þ Leprdb
(type II diabetes) in 7–9-wk old were obtained from Jackson Lab-
oratories (Bar Harbor, Maine). C57BKS.Cg-mþ /þ Leprdb mice
have been used as a model for wound healing in diabetics, es-
pecially for studies involving cytokines and growth factors (Green-
halgh et al, 1990; Okumura et al, 1996). Mice homozygous for the
diabetes spontaneous mutation (Leprdb) become identifiably obese
around 3–4 wk of age. Elevations of plasma insulin begin at 10–14
d and elevation of blood sugar at 4–8 wk. All mice were housed in
the animal facility at the University of Pittsburgh. All animal proto-
cols were approved by IACUC of the University of Pittsburgh.
Plasmids Human TGF-b1 cDNA in pcDNA3.1/GS (Invitrogen Cor-
poration, Carlsbad, California) was amplified in TOP10 competent
cells (Invitrogen Corporation). The plasmid DNA was isolated by
alkaline lysis and purified by ion exchange column chromatogra-
phy (Qiagen Inc., Valencia, California). Plasmid pNGVL-luc, which
encodes luciferase as a reporter protein (National Gene Vector
Laboratory, Ann Arbor, MI) was obtained similarly.
Wounding protocol and treatment A total of 36 C57BL/6 and
136 C57BKS.Cg-mþ /þ Leprdb mice were anesthetized by inha-
lation of Isoflurane and randomly divided into groups to receive
different treatments or control in different experiments. Forty mi-
crograms of plasmid pNGVL-luc (dissolved in 50 mL 1.5  PBS)
intradrmally injected into skin of C57BKS.Cg-mþ /þ Leprdb or
C57BL/6, followed by electorporation using caliper (BTX Gent-
ronics Inc., San Diego, California) or syringe (Liu and Huang, 2002)
electrodes for optimization. Intradermal injection of plasmid
pNGVL-luc was also done for comparison. For the studies of
ELISA and therapeutic effect, two 7  7 mm full thickness exci-
sional wounds were created in parallel on the back of each mouse
after the mice were anesthetized. Human recombinant plasmid
TGF-b1, 30 mg dissolved in 50 mL PBS was intradermally injected to
the lateral sides of a wound followed by electroporation using sy-
ringe electrode. Control mice received either no treatment, elect-
roporation only, intradermal injection of empty plasmid with or
without electroporation or intradermal injection of plasmid TGF-b1
without electroporation.
Measurement of luciferase reporter gene expression Six mice
(12 wounds) in each group were euthanized and skin biopsies were
collected and homogenized. Luciferase gene expression (activity)
was measured using a luminometer. The activity was presented as
relative unit per milligram soluble tissue protein (RLU per mg protein).
Local expression of TGF-b1 using immunoassay At 24 h post-
application, three mice (six wounds) in each group were euthanized
and wound biopsies were harvested and homogenized with
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protease inhibitor (Roche Diagnostics, Indianapolis, IN). TGF-b1
protein concentration was measured with human TGF-b1 ELISA kit
(R&D Systems, Minneapolis, MN) following the supplier’s protocol.
Wound-closure analysis Six mice in each group were examined.
Area of wounds was measured using a caliper at each day, in a
total of 14 d, and evaluated as percentage of wound closure using
the equation
%wound closure ¼ 100  ðwound area at day 0
 wound area at day nÞ=wound area at day 0
Histology Three mice from each group were euthanized and skin
biopsies were harvested at days 3, 5, and 7 postwounding. The
harvested tissue was formalin fixed and embedded in paraffin.
Sections of 4 mm thickness were prepared using a microtome, then
deparaffinized, hydrated, and stained with H&E for observing the
morphology following Degroat’s protocol and picrosirius red stain-
ing using a 0.1% picrosirius red solution (Sweat et al, 1964).
Cell proliferation using anti-BrdU immunhistochemistry At day
3 postwounding, BrdU (Sigma, St Louis, Missouri) labeling was
performed by intraperitoneal injection at a dose of 50 mg per kg at
3 h prior to euthanization. Paraffin sections were taken from spec-
imens at the wound site. The sections were deparaffinized, hy-
drated, pre-treated with 2 N HCl and trypsin (Sigma). BrdU
immunochemical staining was performed by incubation of a rat
monoclonal anti-BrdU antibody (Accurate Chemical & Scientific
Corp., Westbury, New York) for 18 h at 371C. Sections were then
incubated with biotinylated mouse-adsorbed rabbit anti-rat IgG
and were peroxidase labeled with Vetastain Elite ABC Kit (Vector
Laboratories, Burlingame, California). The immunoprecipitate was
visualized by 3,30-diaminobenzidine tetrahydrochloride chromogen
and Gill 1  hematoxylin (Fisher Scientific, Pittsburg, PA) coun-
terstain. Sections were observed under a microscope (Nikon,
Tokyo, Japan), and positively stained cells were counted in three
representative fields at  200 magnification.
Angiogenesis using anti-factor VIII-related antigen immuno-
histochemistry Paraffin sections were taken from specimens at
the wound site at day 7 postwounding. Factor VIII-related antigen
immunochemical staining was performed with incubation of rabbit
polyclonal antisera for factor VIII antigen. All other steps were per-
formed the same way as mentioned in the method for anti-BrdU
staining. Sections were observed at  200 magnification.
Statistical analysis Data were expressed as means  standard
deviation (SD) and analyzed by two-tailed Student’s t test using the
PRISM software program (GraphPad Software, San Diego, Cali-
fornia). The a value (type I error) adjustment was done by using
Bonferroni correction in case of multiple comparisons.
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